A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge.

ABSTRACT:

Objectives

In patients with celiac disease, enteropathy is caused by the entry of gluten peptides into the lamina propria of the intestine, in which their immunogenicity is potentiated by tissue transglutaminase (tTG) and T-helper type 1-mediated immune responses are triggered. Tight junction disassembly and paracellular permeability are believed to have an important role in the transport of gluten peptides to the lamina propria. Larazotide acetate is a tight-junction regulator peptide that, in vitro, prevents the opening of intestinal epithelial tight junctions. The aim of this study was to evaluate the efficacy and tolerability of larazotide acetate in protecting against gluten-induced intestinal permeability and gastrointestinal symptom severity in patients with celiac disease.<

SUBMITTER: Leffler DA 

PROVIDER: S-EPMC3463856 | biostudies-literature | 2012 Oct

REPOSITORIES: biostudies-literature